drugset / Trial / NCT00609856
Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes
Phase 4
Completed
36 enrolled
Skane University Hospital
Medical Research Council · collabSkane County Council Research & Development Foundation · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Pioglitazone and insulin glargine are equally effective in achieving glycemic control in secondary drug failure of type 2 diabetes but the mechanisms of actions are different.
Timeline
- Start
- 2004-04
- Primary completion
- 2006-12
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pioglitazone | Small molecule | 30 mg | — |
| Comparator | insulin glargine | Protein / enzyme biologic | 6 iu | Subcutaneous |
| Comparator | insulin glargine | Protein / enzyme biologic | 10 iu | Subcutaneous |